Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.74 |
| ▸ | CTSB | P07858 | 13/20 | 0.72 |
| ▸ | CTSL | P07711 | 8/20 | 0.72 |
| ▸ | CTSK | P43235 | 6/20 | 0.72 |
| ▸ | CTSS | P25774 | 3/20 | 0.72 |
| ▸ | ELANE | P08246 | 2/20 | 0.72 |
| ▸ | CTSV | O60911 | 1/20 | 0.72 |
| ▸ | PLG | P00747 | 1/20 | 0.72 |
| ▸ | CMA1 | P23946 | 1/20 | 0.72 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644589 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL2332814 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL8244108 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL13412734 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL3822829 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL15450961 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL4259298 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL4259300 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL2332809 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL16143270 | 1.00 | ABCG2 (0.74) | ABCG2CTSBCTSLCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038677-A1 | PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF | SANDOZ AG (CH) | 2015-02-05 | — | — | US | disclosed |
| US-20130131359-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383858-B2 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-26 | — | — | US | disclosed |
| US-8247532-B2 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2407448-A2 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2295401-A2 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2194039-A1 | Process for preparing optically enriched compounds | Vertex Pharmceuticals Incorporated (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | ABCG2 2758/4885CTSB 1530/4885CTSL 2031/4885 |
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | PEPD, CTRL, CTSC | ABCG2 1919/4885CTSB 63/4885CTSL 24/4885 |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | ABCG2 2758/4885CTSB 1530/4885CTSL 2031/4885 |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | PEPD, CTRL, CTSC | ABCG2 1919/4885CTSB 63/4885CTSL 24/4885 |
| US-20150038677-A1 | PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF | ACE, REN, AGT | ABCG2 1894/4885CTSB 1734/4885CTSL 416/4885 |
| US-20130131359-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | REV1, HSD11B1, CYP11B1 | ABCG2 2758/4885CTSB 1530/4885CTSL 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.